Lab Supplies: Turning an Undermanaged Category into a Key Value Driver Through AI

Decentralized procurement typically leaves behind a fragmented supplier landscape, often spanning hundreds or even thousands of vendors. This results in limited visibility into what is being bought, from whom, and at what price. Procurement teams rarely have the bandwidth to analyze spend at the purchase-order level, yet this groundwork is non-negotiable. Without it, optimization remains out of reach. The goal is not transparency for its own sake, but a sharp, prioritized view of where intervention will drive the greatest value.

This is where advanced analytics and, increasingly, GenAI prove their worth. AI models can harmonize thousands of inconsistently labeled PO line items at scale or automatically classify fragmented spend data using a consistent taxonomy, surfacing duplicates and consolidation opportunities. This turns an opaque spend base into an actionable foundation for transformation.

Internal spend data rarely tells the whole story on its own. Involving the organization’s largest suppliers and partners early not only surfaces consolidation opportunities the data would miss, but also builds the trust needed for the commercial conversations that follow.

Product ranges are vast, and similar items are often procured under different specifications or names. This drives unnecessary complexity and limits procurement’s ability to manage the category effectively.

Rationalization cuts through this, taking a category like consumables and systematically reducing the number of approved variants, collapsing dozens of glove, pipette tip, and reagent variants into a defined, fit-for-purpose set.

The result is improved compliance, tangible savings, and a streamlined procurement experience for scientists: a smaller, better-governed set of choices means less time spent searching. Collaboration with the R&D function is essential here: standards only stick if the people who use them helped build them. By aligning technical requirements, operational realities, and commercial objectives from the outset, organizations eliminate the friction that typically derails procurement transformations at the point of execution.

A core lever in lab procurement is consolidation, specifically a deliberate shift of a significant share of demand and spend toward a defined set of preferred suppliers.

Consolidation is most commonly achieved through integrators, distributors that aggregate products from multiple manufacturers and offer a single access point across a broad range of lab supplies. Routing demand through these partners simplifies ordering, reduces the number of supplier interfaces, and builds the volume needed to unlock better commercial and contractual terms.

That said, there is no universal model. Organizations operate along a spectrum, from highly consolidated setups anchored by a single integrator to more distributed approaches with multiple category-specific suppliers. The right configuration depends on the complexity of demand, the degree of standardization achieved, and the extent to which access to specialized or proprietary products remains a priority.

In practice, some tail spend is inevitable and most organizations don’t aim to eliminate it entirely. The most common approach is an integrator-plus model: the bulk of spend is funneled through one primary integrator to capture scale benefits, while specialized products, equipment, or niche requirements are maintained with OEMs or specialist suppliers. The goal is not full consolidation, but deliberate consolidation, knowing where flexibility is worth the cost.

Making this model work, however, requires governance. Volume commitments are often a prerequisite for unlocking contractual savings, and without clear steering mechanisms, users will continue to procure outside preferred channels, quietly eroding the scale benefits consolidation was designed to deliver. Leading organizations address this by moving away from free-form ordering towards guided buying, typically enabled through e-catalogues.

These catalogues provide scientists with access to a curated, pre-approved product set with negotiated pricing built in, replacing the need to navigate fragmented supplier landscapes with a structured, compliant, and effort-light ordering experience.

In practice, there will be exceptions where a scientist needs specific supplies outside the catalogue, and this flexibility must be preserved. The key is to ensure that purchasing outside the catalogue is a deliberate, considered choice rather than a habit. The result is a procurement model that works with scientific workflows rather than against them. This only works if the number of active catalogues is kept in check: overloading scientists with dozens of overlapping options recreates the very complexity guided buying was meant to remove. The catalogue landscape should be revisited on a regular basis, with clear guidance on which catalogue to use for which need and when it makes more sense to approach OEMs directly.